RedHill Biopharma's bowel syndrome drug succeeds in mid-stage study

Oct 3 (Reuters) - RedHill Biopharma Ltd said on Tuesday its drug to treat irritable bowel syndrome with diarrhea met the main goal in a mid-stage study.

The drug, Bekinda, showed improvement in stool consistency response in patients, when compared with a placebo.

(Reporting by Divya Grover in Bengaluru; Editing by Bernard Orr)